Real-world evaluation of bevacizumab plus platinum and paclitaxel for advanced cervical cancer: a single-arm study from Syria
Year: 2026
Type: article
Abstract: Background: Bevacizumab combined with chemotherapy has become a standard first-line treatment for advanced cervical cancer following the Gynecologic Oncology Group (GOG)-240 trial. However, real-world data from low-resource settings, such as Syria, remain limited. Objective: To evaluate the clinical effectiveness of bevacizumab with paclitaxel and either cisplatin or carboplatin in Syrian patients with metastatic or recurrent cervical cancer, using both median progression-free survival (PFS) and restricted mean survival time (RMST) analysis. Methods: A single-arm prospective/retrospective study was conducted at Al-Beiruni University Hospital between January 2023 and December 2024, including 64 patients. Treatment was administered every 21 days with a median of eight cycles per patient (range: 4-20). PFS was estimated using Kaplan-Meier analysis, while RMST was calculated at 3, 6, 9 and 12 months using MedCalc and Python-based tools. Results were compared to the GOG-240 trial as a historical reference. Results: The median PFS was 10.1 months (95% CI: 9.46-10.75), representing a 23.2% increase over GOG-240. RMST analysis demonstrated a consistent survival benefit, with a 25.7% gain at 12 months. The objective response rate reached 61.3%, compared to 48% in the reference trial. Conclusion: This study supports the effectiveness of bevacizumab-based therapy as a first-line option in the Syrian setting, showing sustained clinical benefit and reinforcing the relevance of international guidelines in local oncology practice.
Source: ecancermedicalscience
Authors: Bana Mohamad, Maher Saifo
Institution: Damascus University
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,226
Funder: Damascus University
OpenAlex ID: W7125398455
FWCI:
Cites:
Cited by:
Related to: